Exciting News! Galectin Therapeutics announces positive outcome of the fourth data from its seamless adaptive Phase 2b/3 trial of Belapectin (GR-MD-02) in liver cirrhosis due to NASH/MASH
Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in liver cirrhosis due to NASH/MASH
For detailed information, see the below URL.
Press Release
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
Belapectin is a Galectin-3 inhibitor. It has been reported in PLoS One that this compound improves NASH and fibrosis in preclinical studies in STAM™ mice.
For more information, please see the article at the following URL.
Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
Traber PG and Zomer E, PLoS One. 2013 Dec 18;8(12):e83481.
► https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083481
Further development of Galectin Therapeutics 's Belapectin is expected in the future!
Already published clinical some trial results shown that the STAM™ mice has a high clinical success rate, so would you like to try a pre-clinical study for NASH/MASH using the STAM™ mice?
If you have any interest or questions, please feel free to contact us.
■About STAM™ mice [Click here]